Moderna Settles GSK Patent Suits Over Vaccines
Moderna and GSK agreed to cross-licenses in infectious disease and asked a Delaware court to dismiss GSK's US claims.
Updated on Nov. 6, 2026 in Biotech
Moderna settled GSK's patent lawsuits in the US and Europe that accused its COVID-19 and RSV vaccines of infringing patents tied to lipid nanoparticle technology. The companies granted each other patent cross-licenses in infectious disease, with no payments involved, and asked a Delaware federal court to dismiss GSK's US infringement claims with prejudice.
Why it matters
The settlement removes a lengthy patent dispute over core vaccine delivery technology affecting Spikevax, mNEXSPIKE and mResvia. It also shows how major vaccine makers are resolving intellectual property fights through licensing rather than prolonged litigation.
The cross-licenses carry no payments of any kind, according to the companies, and the Delaware dismissal request is pending. GSK's parallel lawsuit against Pfizer and BioNTech remains unresolved.
The players
Moderna
Moderna is a US biotechnology company known for developing mRNA vaccines, including its COVID-19 vaccine Spikevax and RSV vaccine mResvia.
GlaxoSmithKline (GSK)
GSK is a British multinational pharmaceutical company that sued Moderna and Pfizer over lipid nanoparticle patents.
Pfizer
Pfizer is a US pharmaceutical company that partners with BioNTech on COVID-19 vaccines and faces an ongoing GSK patent suit.
The details
GSK sued Moderna in 2024 alleging that Spikevax, mNEXSPIKE and mResvia infringed its patents on lipid nanoparticle technology. Moderna settled those US and European patent suits on October 28, and on Friday the companies asked a Delaware federal court to dismiss GSK's US claims with prejudice.
Timeline
2022: Moderna brought a patent lawsuit against Pfizer over royalties.
2024: GSK sued Moderna over lipid nanoparticle technology and separately sued Pfizer and BioNTech.
October 28: Moderna settled GSK's US and European patent litigation.
Friday: The companies asked the Delaware court to dismiss GSK's US claims with prejudice.
Market Landscape
Moderna's 2022 lawsuit against Pfizer over mRNA royalties set the stage for a broader wave of vaccine patent fights. The settlement with GSK suggests major vaccine makers are moving toward cross-licensing in infectious disease, even as GSK's suit against Pfizer and BioNTech continues.
The settlement is unlikely to change vaccine availability directly, since the companies stated the cross-licenses involve no payments. Patients using Moderna's COVID-19 and RSV vaccines would see no immediate change from these agreements.
The takeaway
Patent disputes in mRNA and lipid nanoparticle technology are increasingly resolved through licensing agreements rather than prolonged litigation. The Moderna settlement illustrates how competing vaccine developers can trade rights while other lawsuits remain open.
Further reading
For broader context on vaccine technology disputes, see Biotech.
